Key Segmentation:
By Type
-
DHA
-
EPA
-
ALA
By Source
-
Marine Sources
-
Algal Sources
-
Plant Sources
By Application
-
Dietary Supplements
-
Functional Foods and Beverages
-
Pharmaceuticals
-
Infant Formula
-
Animal Nutrition and Pet Food
By Form
-
Softgels
-
Gummies
-
Liquids and Oils
-
Other Forms
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Aker BioMarine, KD Pharma Group, dsm-firmenich, Louis Dreyfus Company, Pelagia (Epax), GC Rieber VivoMega, Corbion, Amarin, Veramaris and Golden Omega.
Key opportunities include algal omega-3, pharmaceutical and clinical nutrition grades, pet and aquaculture nutrition, and growth in emerging markets.
Rising preventive health awareness, supported by clinical evidence and aging populations, is the main growth factor.
By Type, the DHA segment dominated the market in 2025 with an estimated 56.19% share, supported by use in infant formula, prenatal and cognitive health products.
North America dominated the market with a share of 35.08% in 2025, driven by strong supplement use, high awareness and a large cardiovascular patient base.